)
Overview
<ul>
<li>U.S. biotech reported Q4 revenue of $0, down from prior year as milestone revenue fully recognized</li>
<li>Q4 net loss widened yr/yr on higher operating expenses</li>
<li>Company ended 2025 with $318 mln cash, expects runway through 2027</li>
</ul>
Outlook
<ul>
<li>Capricor expects cash balance to support operations through 2027</li>
<li>Company expanding manufacturing capacity in anticipation of potential Deramiocel approval</li>
</ul>
Result Drivers
<ul>
<li>REVENUE DECLINE - Co said Q4 revenue fell to zero as all milestone and upfront payments from Nippon Shinyaku were fully recognized by end-2024</li>
<li>Cash, cash equivalents and marketable securities totaled approximately $318.1 million as of December 31, 2025</li>
<li>HIGHER OPERATING EXPENSES - Co attributed increased Q4 operating expenses to ongoing clinical development, regulatory activities, and commercial launch preparations Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q4 EPS -$0.62</h3>
Q4 Net -$30.20
Income mln
Q4 Basic -$0.62
<h3>EPS</h3>
<h3>Q4 $29.20</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 10 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Capricor Therapeutics Inc is $50.00, about 48.9% above its March 11 closing price of $33.57 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

ARKG

Reuters

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

Capricor Therap

Capricor Theraputics Q4 revenue falls to zero, net loss widens